Patent · US Active

VLP-based bivalent Ebola vaccines and methods of making and using same

US11129886B2 · kind B2 · utility

2Cited by

4References

10Claims

0Family size

Assignee

Children's Hospital Medical Center · US

Inventors

Karnail Singh · Deerfield, US
Paul Spearman · Cincinnati, US

Key dates

Filing date	Mar 28, 2018
Grant date	Sep 28, 2021
Priority date	—
Expiry date	Mar 28, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/14134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.